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chemotherapy during the follow-up. Sensitivity analyses (SA) with cycle number 
controlled as a count variable and a dummy variable (with different thresholds at 6, 
7, 8, 9) were performed to test the robustness of the association. RESULTS: The 
sample included 47 patients, with mean age 75 (ranging 58–95), average baseline PSA 
296 ng/ml (ranging 0.21–2139). The average number of treatment cycles were 10 
(ranging 1–52), with 27 (57.5%) completing <10 and 19 (42.5%) patients ≥10 cycles. 
Median survival was 224 days for <10 group, and 570 days for ≥10 group (P = 
0.0011). The Cox model found a higher likelihood of survival for ≥10 group (HR = 
0.33, P = 0.0117). Consistent results were found in SA. CONCLUSIONS: This study 
suggested that more treatment cycles of D was associated with prolonged OS for 
metastatic PC. The results could be confounded by unadjusted factors, therefore, no 
cause inference can be drawn based on this analysis.
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OBJECTIVES: To examine: 1) formulary coverage for colorectal cancer drugs by 
different hospitals in Taiwan’s National Health Insurance(NHI); 2) how coverage 
varies by hospital level (medical center vs. regional hospital) and location; and 3) how 
coverage varies by drug characterist. METHODS: Nationwide cross-sectional survey 
of regional hospitals and medical centers in Taiwan during June to August, 2009. A 
validated and structured questionnaire was used as the research instrument. The 
outcome variables were formulary coverage, cost sharing tier, and utilization manage-
ment tools (prior authorization, quantity limit, step therapy) for the drugs covered by 
insurance beneﬁt or self-payment. We examined whether there was an association 
between hospital type (level, ownership and location) and drug characteristics (drug, 
costs, and years since approval) with these outcomes. RESULTS: A total of 95 hospi-
tals having oncology department constituted the study group, with respond rate of 
90.5% (86/95). For eight colorectal cancer drugs, the coverage rate ranged from 
98.8% to 74.4% (leucovorin 95.3%; ﬂuorouracil 98.8%; oxaliplatin 95.3%; irinote-
can 88.4%; tegafur-uracil 95.3%; capecitabine 87.2%; cetuximab 74.4%; bevaci-
zumab 79.1%). Capecitabine, cetuximab and bevacizumab are all original brand 
drugs; on the contrary, ﬂuorouracil and tegafur-uracil are all generic sources. Cetux-
imab and bevacizumab have a lower proportion of being regularly prepared (68.8% 
and 76.5%, respectively), comparing to other six drugs with higher proportion than 
85%. Besides the NHI reimbursement guidance, the proportion of having an in-hos-
pital mandated rule was higher for cetuximab and bevacizumab (21.9% and 23.9%, 
respectively). Regardless of differences in hospital level, ownership or locations, the 
two most important factors inﬂuencing the decision making of formulary listing was 
the safety and effectiveness of the drug. CONCLUSIONS: Comparing to target therapy 
drugs, cetuximab and bevacizumab, patients had less accessibility barriers to tradi-
tional colorectal cancer drugs. Furthermore, the geographic differences have an impact 
on accessibility of such drugs by patients.
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OBJECTIVES: Although chemotherapy was proven efﬁcacious for metastatic breast 
cancer (MBC) in clinical trials, lower chemotherapy rates have been observed among 
older patients. This may be due to greater uncertainty in the trade-off between the 
risks and the beneﬁt of chemotherapy associated with older age because of the under-
representation of older patients in cancer clinical trials. These uncertainties may cause 
other non-clinical factors, such as access, to matter more for older patients. We 
examined the effect of access to cancer care, including travel distance to the nearest 
oncologist practice, local area per capita number of oncologists, per capita number of 
hospices, and area chemotherapy rate among stage IV cancer patients across four 
cancers, on age-related difference in chemotherapy use for elderly MBC patients. 
METHODS: The retrospective cohort study used the 1992–2002 SEER-Medicare 
database. Chemotherapy use was deﬁned as at least one chemotherapy-related claim 
within 6 months post diagnosis. We deﬁned ﬁve age subgroups: 66–69, 70–74, 75–79, 
80–84, and 85+. For each age subgroup, we used multivariate logistic regression to 
estimate the effect of access to cancer care on chemotherapy use controlling for covari-
ates. RESULTS: Among 4533 elderly patients with MBC, 30.16% used chemotherapy. 
Chemotherapy rate decreased with age. Subgroup analysis showed that the area treat-
ment rate was positively associated with chemotherapy use in all age groups. In 
addition, among patients who were 85+ years old, local area oncologist supply was 
negatively associated with chemotherapy use. This effect was not observed among 
younger age groups. CONCLUSIONS: Access to cancer care affects chemotherapy 
choice among older patients whose clinical evidence is unclear, which may be attribut-
able to patient preferences and physician concerns of real beneﬁts of chemotherapy 
considering older patients’ limited life expectancy and higher risk of toxicities. The 
more uncertain the evidence with age, the more access may affect chemotherapy 
choice.
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OBJECTIVES: The purpose of this review is to evaluate the published literature to 
assess social inequalities in lung cancer using the ‘cancer disparities grid.’ METHODS: 
Three computerized databases were searched from January 1990 to December 2009 
to identify published English language articles that collected data from study partici-
pants living in the United States. Abstracts were reviewed and articles that dealt with 
social inequality and lung cancer were selected. A total of 96 articles were identiﬁed 
that met the selection criteria. These articles were then classiﬁed into the appropriate 
cell of the cancer disparities grid. RESULTS: The majority of research identiﬁed for 
the grid has focused primarily in domain of inequality, race/ethnicity and racism, and 
one column of the cancer continuum, cancer treatment. About one-third of the articles 
focused on multiple aspects of social inequalities. There were few or no published 
research articles within many of the domains of social inequality along the continuum 
of lung cancer prevention, treatment, and outcomes. CONCLUSIONS: This review 
found only a modest amount of research has been conducted that has examined the 
inﬂuence of social inequalities on lung cancer. Findings suggest that a multidisciplinary 
approach is needed to measure and remedy these social inequalities.
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OBJECTIVES: Disparity in breast cancer treatment is a serious concern in the elderly 
since majority of the breast cancer cases occur in elderly women aged 65 and above. 
We examined racial disparities associated with breast cancer treatment and survival 
in elderly patients with early stage operable breast cancer. METHODS: We studied a 
cohort of 23,110 node positive and 31,572 node negative women aged 65 and over 
diagnosed with incident American Joint Committee on Cancer (AJCC) stage I, II or 
IIIa (early stage operable) breast cancer between January 1, 1991 and December 31, 
2002 using SEER-Medicare data. Multivariate logistic regression analyses were per-
formed to assess the relative odds of receiving surgery (Breast Conserving Surgery, 
BCS versus Mastectomy), chemotherapy (within 6 months of diagnosis) and radiation 
after BCS for African Americans compared to Whites. Cox proportional hazard ratio 
of mortality was used to determine the effectiveness of surgery, chemotherapy and 
radiation after BCS for African Americans compared to Whites after adjustment for 
patient and tumor characteristics. RESULTS: Of the total 54,682 women with breast 
cancer 93.7% were Whites and 6.3% were African Americans. There was a signiﬁcant 
difference between African American and White women in receiving BCS and radia-
tion after BCS; however this difference was explained by patient demographics, tumor 
characteristics and socioeconomic status (SES). Multivariate analysis indicated that 
African American women with node positive and node negative tumors were 21% 
(OR, 0.79; CI, 0.68–0.92) and 19% (OR, 0.81; CI, 0.68–0.97) less likely than White 
women to receive adjuvant chemotherapy. There was no signiﬁcant difference in 
mortality between African American and White women in similarly treated groups. 
CONCLUSIONS: Underutilization of systemic adjuvant chemotherapy in African 
American women requires attention and may serve as potential areas for appropriate 
intervention. Access to quality adjuvant treatments may eliminate observed racial 
differences in outcomes.
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OBJECTIVES: Lung cancer is the most deadly cancer among other types of cancer, 
in both men and women. In 2005, lung cancer accounted for more deaths then breast 
cancer, prostate cancer and colon cancer combined. The purpose of this study was to 
describe the average annual medical resource use and costs incurred by individuals 
with lung cancer in the United States civilian noninstitutionalized population.
METHODS: Data for this study were derived from the 2002–2007 Medical Expen-
diture Panel Survey. Individuals with lung cancer diagnosis were identiﬁed by using 
truncated International Classiﬁcation of Diseases (Ninth Revision) codes obtained 
from household interviews. All individuals >40 years old with health care resource 
use or expenditures for lung cancer were included in this study. Estimates were 
weighted to reﬂect the complex sampling scheme. A societal perspective was adopted 
for this analysis. RESULTS: The average annual mean total health care expenditures 
among individuals with lung cancer were $23,249 (2007 US dollars). Approximately 
34% of average annual direct medical expenditures in individuals with lung cancer 
were for inpatient hospitalization. Annually, lung cancer patients had on average 17 
ofﬁce based provider visits to physician and non-physicians resulting in $5,763 as 
expenses. Further, lung cancer patients had on average 6 outpatient visits annually, 
resulting in $4,304 as expenses. CONCLUSIONS: Lung Cancer causes a large societal 
burden of illness that is expected to increase. This study provides a valuable founda-
tion and historical measure against which to compare other estimates.
